Breakthrough in Egg Defect Could Ease IVF Rollercoaster for Women Over 35
A recent study presented at the Fertility 2026 conference in Edinburgh has brought promising news to women struggling with age-related infertility, particularly those over 35. The breakthrough involves reversing a common defect in eggs that causes them to deteriorate with age, which can significantly reduce the success rates of IVF treatment.
Researchers from Ovo Labs discovered that by supplementing eggs with Shugoshin 1 protein, they were able to almost halve the likelihood of chromosome defects occurring during fertilization. This finding suggests that there may be a window of opportunity in IVF treatment where eggs can be rejuvenated before fertilization, potentially improving overall success rates.
The defect in question involves a crucial protein called Shugoshin 1, which acts as an "adhesive" to keep chromosomes paired and stable. As women age, the levels of this protein decline, leading to chromosome instability and increased risk of failed IVF cycles. The study's results indicate that supplementing eggs with Shugoshin 1 could potentially mitigate this issue.
While the research is still in its early stages and requires further testing to confirm its safety and efficacy, the potential implications are significant. Dr. Agata Zielinska, co-CEO of Ovo Labs, hopes that the breakthrough will enable women to conceive within a single IVF attempt, reducing the emotional rollercoaster often associated with this process.
The study's findings have been welcomed by experts in the field, who acknowledge the long-standing challenge of addressing age-related female infertility. "It's a huge unmet need," said Dr. Agata Zielinska. "This would be a first-in-class solution for improving egg quality."
However, caution is needed, as the research is still experimental and requires further confirmation before it can be widely adopted. The team behind the breakthrough emphasizes that they do not want to overpromise, but rather aim to make a positive impact on the lives of women struggling with infertility.
As the scientific community continues to monitor this progress, one thing is clear: for women over 35 and those facing age-related infertility, there may be hope on the horizon.
A recent study presented at the Fertility 2026 conference in Edinburgh has brought promising news to women struggling with age-related infertility, particularly those over 35. The breakthrough involves reversing a common defect in eggs that causes them to deteriorate with age, which can significantly reduce the success rates of IVF treatment.
Researchers from Ovo Labs discovered that by supplementing eggs with Shugoshin 1 protein, they were able to almost halve the likelihood of chromosome defects occurring during fertilization. This finding suggests that there may be a window of opportunity in IVF treatment where eggs can be rejuvenated before fertilization, potentially improving overall success rates.
The defect in question involves a crucial protein called Shugoshin 1, which acts as an "adhesive" to keep chromosomes paired and stable. As women age, the levels of this protein decline, leading to chromosome instability and increased risk of failed IVF cycles. The study's results indicate that supplementing eggs with Shugoshin 1 could potentially mitigate this issue.
While the research is still in its early stages and requires further testing to confirm its safety and efficacy, the potential implications are significant. Dr. Agata Zielinska, co-CEO of Ovo Labs, hopes that the breakthrough will enable women to conceive within a single IVF attempt, reducing the emotional rollercoaster often associated with this process.
The study's findings have been welcomed by experts in the field, who acknowledge the long-standing challenge of addressing age-related female infertility. "It's a huge unmet need," said Dr. Agata Zielinska. "This would be a first-in-class solution for improving egg quality."
However, caution is needed, as the research is still experimental and requires further confirmation before it can be widely adopted. The team behind the breakthrough emphasizes that they do not want to overpromise, but rather aim to make a positive impact on the lives of women struggling with infertility.
As the scientific community continues to monitor this progress, one thing is clear: for women over 35 and those facing age-related infertility, there may be hope on the horizon.